« Back to Record
Citation APA

McCartney, A., Biagioni, C., Schiavon, G., Bergqvist, M., Mattsson, K., Migliaccio, I., Benelli, M., Romagnoli, D., Bonechi, M., Boccalini, G., Pestrin, M., Galardi, F., De Luca, F., Biganzoli, L., Piccart-Gebhart, M., Gradishar, W. W., Chia, S., Di Leo, A., & Malorni, L. (2019). Prognostic role of serum thymidine kinase 1 activity in patients with hormone receptor–positive metastatic breast cancer: Analysis of the randomised phase III Evaluation of Faslodex versus Exemestane Clinical Trial (EFECT). European journal of cancer, 114, 55-66. doi:10.1016/j.ejca.2019.04.002


Permalink

http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/290063

McCartney, A., Biagioni, C., Schiavon, G., Bergqvist, M., Mattsson, K., Migliaccio, I., Benelli, M., Romagnoli, D., Bonechi, M., Boccalini, G., Pestrin, M., Galardi, F., De Luca, F., Biganzoli, L., Piccart-Gebhart, M., Gradishar, W. W., Chia, S., Di Leo, A., & Malorni, L. (2019). Prognostic role of serum thymidine kinase 1 activity in patients with hormone receptor–positive metastatic breast cancer: Analysis of the randomised phase III Evaluation of Faslodex versus Exemestane Clinical Trial (EFECT). European journal of cancer, 114, 55-66. doi:10.1016/j.ejca.2019.04.002